Used in research for targeting cancers driven by MET and RON receptor tyrosine kinases, particularly in studies involving tumor growth inhibition in models of gastric, liver, and lung cancers. Shows potential in blocking signaling pathways involved in cell proliferation and survival. Investigated for its ability to overcome resistance to other kinase inhibitors. Not approved for clinical use; primarily utilized in preclinical studies to understand oncogenic signaling and evaluate combination therapies.